Ocular Therapeutix, Inc. (OCUL) Loss Submission Form
Levi & Korsinsky announces the commencement of a class action lawsuit in the United States District Court for the District of New Jersey on behalf of shareholders of Ocular Therapeutix, Inc. (NASDAQ : OCUL) who purchased shares between March 10, 2016 and July 11, 2017.
The complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Ocular Therapeutix's management has been misleading investors about DEXTENZA manufacturing issues, including that more than 50% of lots manufactured by Ocular Therapeutix contain bad product; (2) such manufacturing issues could impact the approval of DEXTENZA by the FDA; and (3) as a result, defendants’ public statements were materially false and misleading.
If you suffered a loss in Ocular Therapeutix, Inc. you have until September 5, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.To receive more information, please fill out the form.